Product Description
GMP
AI Product Description
*The following content is generated by AI and is for reference only.
Quetiapine Fumarate is the fumarate salt form of quetiapine, a third-generation atypical antipsychotic medication widely utilized in modern psychiatry. Chemically, it possesses the molecular formula C21H25N3O4S and carries the CAS Registry Number 117971-86-3. As a dibenzothiazepine derivative, its structure allows for potent antagonism of serotonin (5-HT2A) and dopamine (D2) receptors, while exhibiting lower affinity for histamine H1 and muscarinic M1 receptors compared to older agents. This unique receptor profile contributes to its efficacy in treating major psychiatric disorders with a reduced risk of extrapyramidal side effects.
Clinically, Quetiapine Fumarate is primarily indicated for the management of schizophrenia in adults and adolescents, as well as bipolar disorder, including acute manic or mixed episodes and depressive episodes associated with bipolar I disorder. It is also approved for use as an adjunctive treatment for major depressive disorder in adults when antidepressant monotherapy proves insufficient. Beyond these FDA-approved indications, the drug is frequently prescribed off-label for anxiety disorders, insomnia, and agitation in dementia, although such uses require careful risk-benefit analysis due to potential adverse events like sedation, metabolic changes, and orthostatic hypotension.
The drug is available in immediate-release and extended-release formulations, allowing for flexible dosing schedules tailored to individual patient needs. Its pharmacokinetic profile involves extensive hepatic metabolism via cytochrome P450 enzymes, particularly CYP3A4, necessitating dose adjustments when co-administered with strong inhibitors or inducers of this enzyme system. Patients must be monitored regularly for weight gain, glucose dysregulation, and lipid abnormalities during long-term therapy. Despite these considerations, Quetiapine Fumarate remains a cornerstone therapeutic option due to its broad spectrum of activity and favorable tolerability profile relative to first-generation antipsychotics. Ongoing research continues to explore its potential neuroprotective properties and efficacy in emerging psychiatric conditions, solidifying its status as a versatile agent in contemporary psychopharmacology.